ChemDiv

Overview

ChemDiv is a fully integrated target-to-clinic contract research organization (CRO) headquartered in San Diego, CA USA. Over the past 32 years, ChemDiv has successfully completed hundreds of leads, candidates, and new drug programs to treat cancer, neurological, infectious, cardiometabolic, and immune diseases with pharma, biotech, and academic partners globally.

Core Capabilities

Screening Libraries & Compounds

• 1.6 million stock-available compounds
• 12 million managed global available inventory
• 2 trillion structures of synthetically feasible chemistry space
• 114 predesigned screening libraries organized by therapeutic areas, targets, and mechanism of action
• 17 annotated active reference sets with >220,000 compounds and >25,000 targets
• Diversity libraries (2D and 3D) covering billions of compounds
• Preplated libraries representing 30B virtual space of drug-like and lead-like compounds
• Building blocks, inhibitors, approved drugs, and natural-product-based compounds

Integrated Drug Discovery Services

• Custom medicinal chemistry with FTE assignments
• In silico drug design (CADD)
• Discovery biology including ADME and DMPK services
• Functional ex vivo and in vivo models
• Safety and toxicology (GLP and CMP compliant)
• Animal models and specialized research capabilities
• Chemistry, manufacturing, and controls (CMC) support
• Regulatory and clinical trial support

Technology & Innovation

• Hybrid AI/ML-curated discovery platforms
• Proprietary platforms: molecular glues, stabilizers, degraders, covalent and non-covalent binders, bifunctional molecules, new-generation ADCs, RNA and DNA editing
• Computational and structural biology teams
• Synthetic and medicinal chemistry expertise
• Novel compound synthesis at 50,000 molecules per year

Experience & Track Record

• 47 approved drugs developed
• 2,700+ satisfied customers
• 5 R&D hubs worldwide
• Expertise in CNS, oncology, virology, inflammation, cardiometabolic, and immunology
• Validated clinical assets delivered in as little as 18 months
• Intellectual contributions recognized through co-authorship in numerous published patents assigned to customer companies